Developing the next generation of oncolytic immunotherapy
Tumor selective virus replication kills tumors. This releases the full array of neoantigens in an inflamed tumor environment. Both innate and adaptive immune responses are triggered, including through TLR and STING signaling. This provides systemic vaccination and systemic efficacy, and is highly synergistic with immune checkpoint blockade.